146 related articles for article (PubMed ID: 25609999)
1. Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study.
Wiegratz I; Elliesen J; Paoletti AM; Walzer A; Kirsch B
Int J Womens Health; 2015; 7():19-29. PubMed ID: 25609999
[TBL] [Abstract][Full Text] [Related]
2. Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies.
Elliesen J; Trummer D
Int J Womens Health; 2016; 8():351-6. PubMed ID: 27563256
[TBL] [Abstract][Full Text] [Related]
3. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.
Klipping C; Duijkers I; Fortier MP; Marr J; Trummer D; Elliesen J
J Fam Plann Reprod Health Care; 2012 Apr; 38(2):73-83. PubMed ID: 22454003
[TBL] [Abstract][Full Text] [Related]
4. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Jensen JT; Garie SG; Trummer D; Elliesen J
Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
[TBL] [Abstract][Full Text] [Related]
6. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
7. Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen).
Bitzer J; Banal-Silao MJ; Ahrendt HJ; Restrepo J; Hardtke M; Wissinger-Graefenhahn U; Trummer D
Int J Womens Health; 2015; 7():501-9. PubMed ID: 26056491
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study.
Momoeda M; Kondo M; Elliesen J; Yasuda M; Yamamoto S; Harada T
Int J Womens Health; 2017; 9():295-305. PubMed ID: 28496369
[TBL] [Abstract][Full Text] [Related]
9. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
[TBL] [Abstract][Full Text] [Related]
11. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
12. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
Anthuber S; Schramm GA; Heskamp ML
Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
[TBL] [Abstract][Full Text] [Related]
13. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
14. Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg.
Bonassi Machado R; Pompei LM; Andrade R; Nahas E; Guazzelli C; Wender MC; Cruz AM
Int J Womens Health; 2020; 12():235-242. PubMed ID: 32280282
[TBL] [Abstract][Full Text] [Related]
15. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
Keam SJ; Wagstaff AJ
Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
[TBL] [Abstract][Full Text] [Related]
16. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
[TBL] [Abstract][Full Text] [Related]
17. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake.
Duijkers IJM; Heger-Mahn D; Drouin D; Colli E; Skouby S
Contraception; 2016 Apr; 93(4):303-309. PubMed ID: 26708301
[TBL] [Abstract][Full Text] [Related]
20. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
